BioNTech SE
- Open
- 94.35
- Day high
- 95.08
- Day low
- 92.96
- Prev close
- 94.26
- Volume
- 560K
- Mkt cap
- $23.5B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.1
- P/S
- 7.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$5.5M over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions mixed (13F)
BioNTech SE (BNTX) is a Healthcare company listed on NASDAQ. The stock is down 13% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4). Drillr has 1 published research article covering BNTX.
BioNTech SE (BNTX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
BNTX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-2.52 | $-2.28 | +9.5% | $136M | -34.2% |
| Mar 10, 2026 | $-0.19 | $-0.39 | -103.9% | $1.1B | +424.9% |
| Dec 31, 2024 | — | $1.12 | — | $1.2B | — |
| Dec 30, 2023 | — | $2.09 | — | $1.6B | — |
| Dec 31, 2022 | — | $9.97 | — | $4.6B | — |
| Dec 31, 2021 | — | $13.82 | — | $6.3B | — |
| Dec 31, 2020 | — | $1.89 | — | $424M | — |
| Aug 11, 2020 | $-0.29 | $-0.42 | -44.8% | $47M | +341.2% |
| Nov 14, 2019 | $-0.21 | $-0.16 | +23.8% | $31M | -7.7% |
| Mar 31, 2019 | — | $-0.20 | — | $29M | — |
| Dec 31, 2018 | — | $-0.01 | — | $76M | — |
BNTX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 13, 2026 | Hanekamp Annemarieofficer: Chief Commercial Officer | Grant | 10,069 | — |
| May 13, 2026 | Zapata Gomez Ramonofficer: Chief Financial Officer | Grant | 18,879 | — |
| May 13, 2026 | Zapata Gomez Ramonofficer: Chief Financial Officer | Grant | 15,103 | — |
| May 13, 2026 | Ryan James Timothy Patrickofficer: See remarks. | Grant | 12,586 | — |
| May 13, 2026 | Ryan James Timothy Patrickofficer: See remarks. | Grant | 10,069 | — |
| May 13, 2026 | Poetting Sierkofficer: Chief Operating Officer | Grant | 12,586 | — |
| May 13, 2026 | Poetting Sierkofficer: Chief Operating Officer | Grant | 10,069 | — |
| May 13, 2026 | Jimenez Kylieofficer: Chief People Officer | Grant | 10,488 | — |
| May 13, 2026 | Jimenez Kylieofficer: Chief People Officer | Grant | 8,391 | — |
| May 13, 2026 | Hanekamp Annemarieofficer: Chief Commercial Officer | Grant | 12,586 | — |
| Apr 23, 2026 | Poetting Sierkofficer: Chief Operating Officer | Sell | 50,000 | $110.56 |
Source: BNTX SEC Form 4 filings, latest May 13, 2026. For informational purposes only — not investment advice.
See the full BNTX insider & 13F page →BioNTech SE company profile
Overview
BioNTech SE (NASDAQ:BNTX) is a German biotechnology company founded in 2008 and headquartered in Mainz, Germany. The company gained global prominence during the COVID-19 pandemic as the developer of the first approved mRNA-based COVID-19 vaccine in partnership with Pfizer. Originally focused on developing immunotherapies for cancer treatment, BioNTech has evolved into a leading mRNA technology platform company with applications spanning oncology, infectious diseases, and rare diseases. The company went public on NASDAQ in October 2019 and has since established itself as a pioneer in mRNA therapeutics with a robust pipeline of over 20 oncology programs and multiple infectious disease vaccine candidates.
Business
BioNTech operates in the biotechnology industry, specifically focusing on mRNA (messenger RNA) technology to develop immunotherapies and vaccines. The company's core technology platform uses synthetic mRNA to instruct cells to produce specific proteins that can trigger immune responses against diseases. The company operates across three main business segments: 1. COVID-19 Vaccines (Primary Revenue Driver): BioNTech's COVID-19 vaccine, developed in partnership with Pfizer, uses mRNA technology to instruct cells to produce the spike protein found on the coronavirus surface, thereby training the immune system to recognize and fight the virus. This vaccine became the first mRNA-based vaccine approved for human use and has generated the majority of the company's revenue since 2020. The company continues to develop variant-adapted vaccines and is working on next-generation formulations. 2. Oncology Pipeline (Future Growth Driver): The company has over 20 oncology programs in development across four main therapeutic approaches. FixVac products are "off-the-shelf" mRNA cancer vaccines targeting shared tumor antigens, while iNeST (individualized Neoantigen Specific immunoTherapy) creates personalized cancer vaccines based on each patient's unique tumor mutations. The company also develops antibody-drug conjugates (ADCs) like BNT323 for HER2-positive cancers, bispecific antibodies such as BNT327 that simultaneously target PD-L1 and VEGF pathways, and CAR-T cell therapies that engineer patients' immune cells to fight cancer. 3. Infectious Disease Vaccines: Beyond COVID-19, BioNTech is developing mRNA vaccines for influenza, shingles, tuberculosis, malaria, and other infectious diseases. The company is also working on combination vaccines, such as a COVID-19/influenza combination vaccine with Pfizer. Based on recent financial results, COVID-19 vaccines account for approximately 95% of current revenues, while the oncology and other infectious disease programs represent the company's future growth potential but do not yet generate significant commercial revenue.
Revenue model
BioNTech generates revenue primarily through product sales of its COVID-19 vaccine, with Pfizer serving as the primary commercialization partner globally. The company receives a share of gross profits from vaccine sales, with the exact percentage varying by region and contract terms. For COVID-19 vaccines, BioNTech typically retains manufacturing responsibilities for certain regions while Pfizer handles global distribution and marketing. The company's business model faces several margin-influencing factors: Positive margin drivers include the high gross margins typical of mRNA vaccines (historically around 80-85% for COVID-19 vaccines), the scalability of mRNA manufacturing once established, and the potential for premium pricing of personalized cancer vaccines. The company's strong intellectual property position in mRNA technology and established manufacturing capabilities provide competitive advantages. Negative margin pressures stem from the substantial R&D investments required for biotechnology development, with the company spending €2.6-2.8 billion annually on research and development. The COVID-19 vaccine market is experiencing declining demand as the pandemic transitions to endemic status, leading to inventory write-downs and reduced pricing power. Additionally, the company faces increasing competition in both mRNA technology and cancer immunotherapy markets, while regulatory approval processes for new therapies remain lengthy and expensive. The company's future profitability depends heavily on successfully transitioning from COVID-19 vaccine dependence to a diversified portfolio of oncology and infectious disease products. With multiple oncology programs approaching potential commercial launch around 2026, BioNTech aims to establish recurring revenue streams from cancer treatments, which typically command higher prices and longer treatment durations than vaccines.
Competitive moat
BioNTech's competitive moat centers on its pioneering position in mRNA technology and extensive intellectual property portfolio, though this moat faces increasing competitive pressure. The company's primary advantages include being first-to-market with an approved mRNA vaccine, which provided valuable real-world manufacturing and regulatory experience that competitors lack. BioNTech has developed sophisticated mRNA design and manufacturing capabilities, including AI-driven neoantigen selection for personalized cancer vaccines and specialized cold-chain logistics expertise. However, the company's moat strength is moderate and narrowing. While BioNTech maintains technological leadership, mRNA technology itself is not proprietary to the company, and major pharmaceutical companies like Moderna, Merck, and others are rapidly advancing their own mRNA platforms. The COVID-19 vaccine market, which provided BioNTech's initial competitive advantage, is becoming increasingly commoditized with multiple approved vaccines and declining demand. In oncology, BioNTech faces intense competition from established players with deeper resources and more extensive commercial capabilities. Companies like Roche, Bristol Myers Squibb, and Merck have stronger positions in cancer immunotherapy markets that BioNTech is attempting to enter. The company's personalized cancer vaccine approach, while innovative, requires complex manufacturing and regulatory pathways that may limit scalability. Potential disruption could come from advances in alternative therapeutic modalities such as cell therapy, gene editing technologies like CRISPR, or novel drug delivery systems that could make mRNA approaches less attractive. Additionally, if larger pharmaceutical companies successfully develop competing mRNA platforms with superior manufacturing efficiency or clinical outcomes, BioNTech's first-mover advantage could erode quickly. The company's relatively small size compared to Big Pharma competitors also limits its ability to fund large-scale clinical trials and global commercialization efforts independently.
Risks & safety
BioNTech maintains a strong financial position with substantial cash reserves, though the company is currently unprofitable and burning cash on R&D investments. • Liquidity and Solvency: Cash and short-term investments of €10.6 billion provide significant runway for operations. Current ratio of 7.5x and quick ratio of 7.3x indicate excellent short-term liquidity. Debt-to-equity ratio of just 1.3% shows minimal leverage risk. • Cash Burn: Operating cash flow turned negative in recent quarters, with free cash flow of -€265 million in 2024. The company is investing heavily in R&D (€2.6-2.8 billion annually) while COVID-19 revenues decline. At current burn rates, cash reserves provide approximately 4-5 years of runway. • Valuation Metrics: Trading at 1.4x book value with negative earnings makes traditional valuation challenging. EV/EBITDA is negative due to current losses. Graham net-net value of €62 suggests the stock trades near liquidation value, indicating either value opportunity or fundamental concerns. • Other Considerations: Revenue concentration risk from COVID-19 vaccine dependence, regulatory approval uncertainties for oncology pipeline, and intense competition in target markets present additional risks to financial stability.
Recent development
Over the past few years, BioNTech has executed a strategic transformation from a COVID-19 vaccine company to a diversified mRNA therapeutics platform. The company has significantly expanded its oncology pipeline, advancing multiple programs into late-stage clinical trials with the goal of launching its first cancer therapy by 2026. Key strategic developments include the focus on two "pan-tumor" opportunities: BNT327, a bispecific antibody targeting both PD-L1 and VEGF pathways, and mRNA cancer immunotherapies including both personalized (iNeST) and off-the-shelf (FixVac) vaccines. The company achieved a major milestone when BNT111, its FixVac melanoma vaccine, met its primary endpoint in Phase 2 trials, validating the off-the-shelf mRNA cancer vaccine approach. BioNTech has also made strategic acquisitions, including the recent closure of the Biotheus acquisition to strengthen its antibody-drug conjugate capabilities. The company is building specialized manufacturing infrastructure, including a pilot facility in Mainz for personalized mRNA vaccine production, and has invested heavily in AI-driven neoantigen selection technology to improve the precision of its cancer vaccines. In infectious diseases beyond COVID-19, the company has initiated clinical trials for vaccines targeting shingles, tuberculosis, malaria, and other pathogens, while also developing combination vaccines such as a COVID-19/influenza combination with Pfizer. The company continues to adapt its COVID-19 vaccine for new variants, maintaining its market leadership position while preparing for the transition to endemic vaccination patterns. Organizational changes include the appointment of a new CFO, Ramón Zapata, starting July 2025, and continued investment in commercial capabilities as the company prepares for its first oncology product launches. The company has set ambitious goals to have over 10 potentially registrational trials ongoing by 2024 and aims to achieve peak oncology sales potential exceeding €10 billion across multiple indications by 2030.
BNTX company profile · for informational purposes only — not investment advice.
Track BNTX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free